Condition
HER2-positive Advanced Breast Cancer
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 10 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
10 shownTrastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain MetastasesNCT07100600 · 2025-08-30
RECRUITINGTQB2930 Injection for the Treatment of HER2-positive Advanced Breast CancerNCT07047365 · 2025-07-25
RECRUITINGOpen-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsNCT06625775 · 2024-10-29
RECRUITINGEfficacy and Safety of Inetetamab Combined With Pyrotinib and Vinorelbine in ABCNCT05856383 · 2022-03-16
RECRUITINGHER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast CancerNCT06595563 · 2026-06-30
TERMINATEDT-DM1 Combined With CDK4/6 Inhibitor RibociclibNCT06481956 · 2023-10-25
ENROLLING_BY_INVITATIONDP303c in Patients With HER2-positive Advanced Breast CancerNCT05901935 · 2023-07-01
NOT_YET_RECRUITINGRWS of Inetetamab HER2 Positive Advanced Breast CancerNCT04963608 · 2021-07-01
UNKNOWNPyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast CancerNCT04903652 · 2021-01-01
COMPLETEDThe Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast CancerNCT04185649 · 2018-07-01
UNKNOWNCommon interventions
TrastuzumabDRUG2BAT8001 for injectionBIOLOGICAL1BBO-10203DRUG1BevacizumabDRUG1CapecitabineDRUG1Capecitabine tabletsDRUG1DP303cDRUG1FOLFOXDRUG1FSRT or WBRTRADIATION1FulvestrantDRUG1InetetamabDRUG1Inetetamab Combined With Pyrotinib and VinorelbineDRUG1LapatinibDRUG1Pyrotinib MaleateDRUG1RibociclibDRUG1Ribociclib Oral TabletDRUG1TQB2930+ chemotherapyDRUG1Trastuzumab emtansineDRUG1Trastuzumab RezetecanDRUG1Trastuzumab+ chemotherapyDRUG1VinorelbineDRUG1Vinorelbine TartrateDRUG1
Leading sponsors
Bio-Thera Solutions
1
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
1
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
1
Henan Cancer Hospital
1
Jules Bordet Institute
1
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
1
Tianjin Medical University Cancer Institute and Hospital
1
Zhejiang Cancer Hospital
1
Zheng Yabing
1
Zhiyong Yu
1
Trial status mix
RECRUITING4
UNKNOWN2
COMPLETED1
ENROLLING_BY_INVITATION1
NOT_YET_RECRUITING1
TERMINATED1
Phase mix
PHASE24
PHASE33
PHASE11
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.